Warning To Patients: Beware Of This New Drug For kidney cancer
According to recently-released research findings, next-generation blood-thinning drug Xarelto may pose additional risk to patients who are already suffering from kidney cancer. The study, based on data taken from the Department of Defense electronic medical records system, found that those with existing kidney ailments were significantly more likely to experience dangerous internal bleeding while taking the drug than patients without such a condition.
Details of Xarelto study
The authors of this study, presented at a meeting of the American Heart Association, examined medical data aggregated from over 44,000 patients, 6,921 of whom had previously been diagnosed with kidney cancer. Of those individuals who also used the blood thinning drug Xarelto, 312 experienced significant internal bleeding events.The 36,891 patients within the study who did not have existing kidney cancer and who also used Xarelto registered 981 such bleeding incidents. While the findings reveal a heightened risk of bleeding for kidney patients taking the drug as compared to those without renal problems, the bleeding events were not found to be linked to a higher rate of death as a result.It is also worth noting that patients suffering from both kidney cancer and heart trouble demonstrated an even higher likelihood of a major bleeding event than patients with kidney cancer alone.
Findings underscore growing concerns about Xarelto
The potential dangers of Xarelto side effects has been the topic of research and litigation in recent months. Brought to the American market in 2011, Xarelto (rivaroxoban) was touted as a breakthrough, next-generation anticoagulant medication designed for individuals at heightened risk of pulmonary embolism or deep vein thrombosis. The drug was hailed as being far superior to predecessor blood thinner warfarin, which had long been the standard option for large numbers of patients.Xarelto was represented as being a more convenient choice in that it did not require the sort of ongoing medical monitoring necessary for patients taking warfarin. However, a primary drawback of Xarelto has always been the absence of an antidote that could reverse its blood-thinning effects in the event of a serious bleed. In contrast, the effects of warfarin have always been reversible in relatively short order with an appropriate dose of Vitamin K.